APOB and familial hyperaldosteronism: Thus, it is likely that the PCSK9-i could impact on circulating apoB-rich lipoproteins not only quantitatively but also qualitatively improving the overall lipid profile, and possibly explaining the lower CLC observed in our cohort of FH subjects.